JTCS Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Pat O. Daily
Walter P. Dembitsky
Nestor F. Dans
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Daily, P. O.
Right arrow Articles by Dans, N. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daily, P. O.
Right arrow Articles by Dans, N. F.

J Thorac Cardiovasc Surg 1994;108:99-108
© 1994 Mosby, Inc.


CARDIOPULMONARY BYPASS,
MYOCARDIAL MANAGEMENT, AND SUPPORT TECHNIQUES

Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass graftingA randomized, prospective, double-blind study

Pat O. Daily, MD, Jeffrey A. Lamphere, PA-C, Walter P. Dembitsky, MD, Robert M. Adamson, MD, Nestor F. Dans, MD


San Diego, Calif.

From Sharp Memorial Hospital, San Diego, Calif.

Address for reprints: Pat O. Daily, MD, 8010 Frost St., Suite 501, San Diego, CA 92123.

Abstract

The prophylactic use of aprotinin has recently been reported to be associated with a significant decrease in blood loss in patients undergoing cardiopulmonary bypass procedures. One of the primary effects of aprotinin is prevention of plasmin degradation of platelet function. Because aprotinin is commercially unavailable in the United States at this time, we evaluated epsilon-aminocaproic acid with respect to decreased perioperative blood loss. We prospectively randomized 40 patients undergoing first-time coronary artery bypass grafting without prior sternotomy into two groups: one group (n = 21) received prophylactic and preincision epsilon-aminocaproic acid and the other (n = 19) received a placebo. No significant differences existed between patient groups with respect to age, body surface area, cardiopulmonary bypass time, and aortic crossclamp time. Cumulative blood loss at 4, 8, 12, and 24 hours after chest closure was significantly less in the epsilon-aminocaproic acid group (426 ± 242 ml versus 634 ± 224 ml, p = 0.002, at 12 hours). Only one patient receiving epsilon-aminocaproic acid was given blood or blood components compared to five patients in the placebo group (p < 0.02). D-dimers and fibrin split products were significantly less prevalent in the epsilon-aminocaproic acid group (at 4 hours: 0/20 versus 7/16, p < 0.002 and 5/20 versus 12/19, p < 0.05, respectively). None of the patients had a perioperative myocardial infarction or cerebrovascular accident. The prophylactic administration of epsilon-aminocaproic acid results in a significant decrease in blood loss in patients undergoing first-time coronary artery bypass grafting, and blood transfusion requirements are significantly less. It may be important to administer epsilon-aminocaproic acid before skin incision to be optimally effective. (J THORAC CARDIOVASC SURG 1994;108:99-108)




This article has been cited by other articles:


Home page
CirculationHome page
J. R. Brown, N. J.O. Birkmeyer, and G. T. O'Connor
Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery
Circulation, June 5, 2007; 115(22): 2801 - 2813.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
M. E. Jessen
Pro: Heparin-Coated Circuits Should be Used for Cardiopulmonary Bypass
Anesth. Analg., December 1, 2006; 103(6): 1365 - 1369.
[Full Text] [PDF]


Home page
JCOHome page
K. K. Ballen, P. S. Becker, B. Y. Yeap, B. Matthews, D. H. Henry, and P. A. Ford
Autologous Stem-Cell Transplantation Can Be Performed Safely Without the Use of Blood-Product Support
J. Clin. Oncol., October 15, 2004; 22(20): 4087 - 4094.
[Abstract] [Full Text] [PDF]


Home page
Card Surg AdultHome page
R. Salenger, J. S. Gammie, and T. J. Vander Salm
Postoperative Care of Cardiac Surgical Patients
Card. Surg. Adult, January 1, 2003; 2(2003): 439 - 469.
[Full Text]


Home page
Anesth. Analg.Home page
M. Stafford-Smith, B. Phillips-Bute, D. N. Reddan, J. Black, and M. F. Newman
The Association of {epsilon}-Aminocaproic Acid with Postoperative Decrease in Creatinine Clearance in 1502 Coronary Bypass Patients
Anesth. Analg., October 1, 2000; 91(5): 1085 - 1090.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
R. Saleem, M. Bigham, E. Spitznagel, and G. J. Despotis
The Effect of Epsilon-Aminocaproic Acid on HemoSTATUS(R) and Kaolin-Activated Clotting Time Measurements
Anesth. Analg., June 1, 2000; 90(6): 1281 - 1285.
[Abstract] [Full Text] [PDF]


Home page
Asian Cardiovasc. Thorac. Ann.Home page
S. Chauhan, A. K. Bisoi, B. H. Rao, M S. Rao, N. Saxena, P. Venugopal, S. Chauhan, A. K. Bisoi, B. H. Rao, M S. Rao, et al.
Dosage of Epsilon-Aminocaproic Acid to Reduce Postoperative Blood Loss
Asian Cardiovasc Thorac Ann, March 1, 2000; 8(1): 15 - 18.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. De Bonis, F. Cavaliere, F. Alessandrini, E. Lapenna, F. Santarelli, U. Moscato, R. Schiavello, and G. F. Possati
TOPICAL USE OF TRANEXAMIC ACID IN CORONARY ARTERY BYPASS OPERATIONS: A DOUBLE-BLIND, PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED STUDY
J. Thorac. Cardiovasc. Surg., March 1, 2000; 119(3): 575 - 580.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
E. P. Stover, L. C. Siegel, P. A. Hood, G. E. O’Riordan, and T. R. McKenna
Platelet-Rich Plasma Sequestration, with Therapeutic Platelet Yields, Reduces Allogeneic Transfusion in Complex Cardiac Surgery
Anesth. Analg., March 1, 2000; 90(3): 509 - 516.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. J. Munoz, N. J. O. Birkmeyer, J. D. Birkmeyer, G. T. O'Connor, and L. J. Dacey
Is {epsilon}-Aminocaproic Acid as Effective as Aprotinin in Reducing Bleeding With Cardiac Surgery? : A Meta-Analysis
Circulation, January 12, 1999; 99(1): 81 - 89.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
P. M. Mannucci
Hemostatic Drugs
N. Engl. J. Med., July 23, 1998; 339(4): 245 - 253.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. P. Pelletier, S. Solymoss, A. Lee, and R. C.-J. Chiu
Negative Reexploration for Cardiac Postoperative Bleeding: Can It Be Therapeutic?
Ann. Thorac. Surg., April 1, 1998; 65(4): 999 - 1002.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
B. Eberle, E. Mayer, G. Hafner, J. Heinermann, M. Dahm, W. Prellwitz, W. Dick, and H. Oelert
High-Dose {epsilon}-Aminocaproic Acid Versus Aprotinin: Antifibrinolytic Efficacy in First-Time Coronary Operations
Ann. Thorac. Surg., March 1, 1998; 65(3): 667 - 673.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
J.-F. Hardy, S. Belisle, C. Dupont, F. Harel, D. Robitaille, M. Roy, and L. Gagnon
Prophylactic Tranexamic Acid and {epsilon}-Aminocaproic Acid for Primary Myocardial Revascularization
Ann. Thorac. Surg., February 1, 1998; 65(2): 371 - 376.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
T. J. Vander Salm
Use of epsilon-aminocaproic acid to reduce bleeding
J. Thorac. Cardiovasc. Surg., June 1, 1997; 113(6): 1126 - 1127.
[Full Text]


Home page
J. Thorac. Cardiovasc. Surg.Home page
T. J. Vander Salm, S. Kaur, R. A. Lancey, O. N. Okike, A. T. Pezzella, R. F. Stahl, L. Leone, J.-M. Li, C. R. Valeri, and A. D. Michelson
REDUCTION OF BLEEDING AFTER HEART OPERATIONS THROUGH THE PROPHYLACTIC USE OF EPSILON-AMINOCAPROIC ACID
J. Thorac. Cardiovasc. Surg., October 1, 1996; 112(4): 1098 - 1107.
[Abstract] [Full Text]


Home page
CLIN APPL THROMB HEMOSTHome page
S. M. Lanzkron and W. R. Bell
State-of-the-Art Review : Management of Patients Who Require Invasive Procedures Immediately Following Thrombolytic Therapy
Clinical and Applied Thrombosis/Hemostasis, July 1, 1996; 2(3): 158 - 163.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
D. Katsaros, M. Petricevic, N. J. Snow, D. D. Woodhall, and R. Van Bergen
Tranexamic Acid Reduces Postbypass Blood Use: A Double-Blinded, Prospective, Randomized Study of 210 Patients
Ann. Thorac. Surg., April 1, 1996; 61(4): 1131 - 1135.
[Abstract] [Full Text]


Home page
Ann. Thorac. Surg.Home page
J. A. Magovern, T. Sakert, D. H. Benckart, J. A. Burkholder, G. A. Liebler, G. J. Magovern Sr, and G. J. Magovern Jr
A Model for Predicting Transfusion After Coronary Artery Bypass Grafting
Ann. Thorac. Surg., January 1, 1996; 61(1): 27 - 32.
[Abstract] [Full Text]


Home page
Ann. Thorac. Surg.Home page
L. G. Svensson, J. Sun, E. Nadolny, and W. A. Kimmel
Prospective Evaluation of Minimal Blood Use for Ascending Aorta and Aortic Arch Operations
Ann. Thorac. Surg., June 1, 1995; 59(6): 1501 - 1508.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1994 by The American Association for Thoracic Surgery.